BiotechTube
Home/Flavocure Biotech/Ngeh J. Toyang, PhD
NJ

Ngeh J. Toyang, PhD

CEO, Co-Founder & Interim CSO

Flavocure Biotech

Therapeutic Areas

OncologyNeurology

Flavocure Biotech Pipeline

DrugIndicationPhase
CaflanonePancreatic Cancer / PancreatoblastomaIND ready
CSF1-R ProgramGlioblastoma (GBM) / MyelomaPre-Clinical
Caflanone / HLNT-06CNS DiseasesPre-Clinical
NCDx™CNS Diseases (Diagnostic)Pre-Clinical
NanoCaflanone™ PlatformOncology (e.g., brain metastases)Pre-Clinical
NCThera™CNS & OncologyPre-Clinical

Leadership Team at Flavocure Biotech

HC
Henry C. Lowe, PhD
Executive Chairman, Founder
DB
David Brooks, MD, PhD
Interim Chief Medical Officer
TL
Thomas Lang, PhD
VP, Quality and Regulatory Affairs
View full Flavocure Biotech profile